Kingworld Medicines Group Limited has circulated a proxy form ahead of its annual general meeting scheduled for 29 May 2026 at 11:00 a.m. in Hong Kong. Shareholders are invited to vote on seven ordinary resolutions that frame the company’s governance and capital-management roadmap for the year ahead.

The board will first seek approval of the audited consolidated financial statements for the year ended 31 December 2025, together with the accompanying directors’ and auditor’s reports.

Two board seats are up for confirmation: • Executive Director Zhao Li Sheng is proposed for re-election, with authority granted to the board to set his remuneration. • Independent Non-Executive Director Duan Jidong is likewise nominated for another term, with remuneration to be fixed by the board.

Auditor continuity is addressed through the proposed re-appointment of Crowe (HK) CPA Limited until the next AGM, with the board empowered to determine audit fees.

The meeting will also ask shareholders to refresh the company’s capital mandates: • A general mandate to allot, issue and deal with additional shares— including any sale or transfer of treasury shares—up to 20% of the issued share capital (excluding treasury shares) as at the date of approval. • Authority to repurchase up to 10% of issued shares (excluding treasury shares). • An extension of the issuance mandate by adding back the number of shares repurchased under the buy-back mandate.

Shareholders holding multiple shares are entitled to appoint more than one proxy, and completed proxy forms must reach Tricor Investor Services Limited no later than 48 hours before the meeting. Attendance in person will override any submitted proxy instructions.